![Tina Albertson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tina Albertson
Chief Tech/Sci/R&D Officer at
CARIBOU BIOSCIENCES, INC.
Net worth: 161 714 $ as of 31/05/2026
Profile
Tina Albertson is currently Chief Medical Officer at Caribou Biosciences, Inc. since 2024.
Formerly, Dr. Albertson was Chief Medical Officer & Head-Development at Lyell Immunopharma, Inc. from 2020 to 2023, Vice President-Global Drug Development at Juno Therapeutics, Inc. from 2015 to 2020, and Medical Director at Seagen, Inc. from 2010 to 2015.
Education includes a doctorate from Stanford University, a doctorate from the University of Washington, and an undergraduate degree from the University of Oregon.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 24/02/2026 | 68,523 ( 0.07% ) | 161 714 $ | 31/05/2026 |
Tina Albertson active positions
| Companies | Position | Start |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 12/08/2024 |
Former positions of Tina Albertson
| Companies | Position | End |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/11/2023 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/04/2020 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 01/01/2015 |
Training of Tina Albertson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
46
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
- Stock Market
- Insiders
- Tina Albertson
Choose MarketScreener 
